速递|礼来全球首个口服GLP-1降压药,在华获批临床!

GLP1减重宝典
May 07, 2025

整理 | GLP1减重宝典内容团队5月6日,据中国药品审评中心(CDE)官网信息,礼来公司(Eli Lilly and Company)提交的Orforglipron胶囊获得临床试验默示许可,拟用于治疗患有高血压的成人肥胖或超重人群。Orforglipron是一种每日一次的在研口服GLP-1受体激动剂,为非肽类小分子药物,服用时间不受限制,无需配合饮食调整。该药物最初由中外制药(Chugai ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10